Hal Barron Leaves GSK With A Stronger Pipeline But Still Awaiting Inflection
R&D Spending Still Lags Behind Peers
Executive Summary
Research chief Barron is departing before his turnaround of GSK is fully realized but the consumer division spin-out could unlock new R&D money to help it challenge the sector’s leaders.
You may also be interested in...
Hal Barron To Depart GSK To Head Up New Biotech
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.